Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer
JAMA Network Open · 09.04.2024 · 7 (4) · e245635
DOI: 10.1001/jamanetworkopen.2024.5635 ↗Kurz gefasst
Kontrollierte klinische Studie in der Zeitschrift JAMA Network Open, online erschienen am 09.04.2024. Verfasst von Davide Ciardiello und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milan, Italy. Hauptthemen laut MEDLINE: Colonic Neoplasms, Liver Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance The available evidence regarding anti–epidermal growth factor receptor (EGFR) inhibitor rechallenge in patients with refractory circulating tumor DNA (ctDNA) RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) is derived from small retrospective and prospective studies.
Objective
To evaluate the efficacy of anti-EGFR rechallenge in patients with refractory ctDNA RAS/BRAF wt mCRC. Design, Setting, and Participants This nonrandomized controlled trial used a pooled analysis of individual patient data from patients with RAS/BRAF wt ctDNA mCRC enrolled in 4 Italian trials (CAVE, VELO, CRICKET, and CHRONOS) and treated with anti-EGFR rechallenge between 2015 and 2022 (median [IQR] follow-up, 28.1 [25.8-35.0] months).
Intervention
Patients received anti-EGFR rechallenge therapy, including cetuximab plus avelumab, trifluridine-tipiracil plus panitumumab, irinotecan plus cetuximab, or panitumumab monotherapy. Main Outcomes and Measures Overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and disease control rate (DCR) were calculated. Exploratory subgroup analysis evaluating several clinical variables was performed. Safety was reported.
Results
Overall, 114 patients with RAS/BRAF wt ctDNA mCRC (median [IQR] age, 61 [29-88] years; 66 men [57.9%]) who received anti-EGFR rechallenge as experimental therapy (48 received cetuximab plus avelumab, 26 received trifluridine-tipiracil plus panitumumab, 13 received irinotecan plus cetuximab, and 27 received panitumumab monotherapy) were included in the current analysis. Eighty-three patients (72.8%) had received 2 previous lines of therapy, and 31 patients (27.2%) had received 3 or more previous lines of therapy. The ORR was 17.5% (20 patients), and the DCR was 72.3% (82 patients). The median PFS was 4.0 months (95% CI, 3.2-4.7 months), and the median OS was 13.1 months (95% CI, 9.5-16.7 months). The subgroup of patients without liver involvement had better clinical outcomes. The median PFS was 5.7 months (95% CI, 4.8-6.7 months) in patients without liver metastasis compared with 3.6 months (95% CI, 3.3-3.9 months) in patients with liver metastasis (hazard ratio, 0.56; 95% CI, 0.37-0.83; P = .004). The median OS was 17.7 months (95% CI, 13-22.4 months) in patients without liver metastasis compared with 11.5 months (95% CI, 9.3-13.9 months) in patients with liver metastasis (hazard ratio, 0.63; 95% CI, 0.41-0.97; P = .04). Treatments showed manageable toxic effects. Conclusions and Relevance These findings suggest that anti-EGFR rechallenge therapy has promising antitumor activity in patients with refractory ctDNA RAS/BRAF wt mCRC. Within the limitation of a subgroup analysis, the absence of liver metastases was associated with significant improved survival. Trial Registration ClinicalTrials.gov Identifiers: NCT02296203 ; NCT04561336 ; NCT03227926 ; NCT05468892
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milan, Italy.
- Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy.
- Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milano, Italy.
- Department of Hematology, Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milano, Italy.
- IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy.
- Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
Zitieren
APA
Ciardiello, D., Martinelli, E., Troiani, T., Mauri, G., Rossini, D., Martini, G., Napolitano, S., Famiglietti, V., Del Tufo, S., Masi, G., Santini, D., Avallone, A., Pietrantonio, F., Lonardi, S., Di Maio, M., Zampino, M. G., Fazio, N., Bardelli, A., Siena, S., …, & Ciardiello, F. (2024). Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer. JAMA Network Open, 7(4), e245635. https://doi.org/10.1001/jamanetworkopen.2024.5635
Vancouver
Ciardiello D, Martinelli E, Troiani T, Mauri G, Rossini D, Martini G, et al. Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer. JAMA Network Open. 2024;7(4):e245635. doi:10.1001/jamanetworkopen.2024.5635
BibTeX
@article{Ciardiello2024,
author = {Ciardiello, Davide and Martinelli, Erika and Troiani, Teresa and Mauri, Gianluca and Rossini, Daniele and Martini, Giulia and Napolitano, Stefania and Famiglietti, Vincenzo and Del Tufo, Sara and Masi, Gianluca and Santini, Daniele and Avallone, Antonio and Pietrantonio, Filippo and Lonardi, Sara and Di Maio, Massimo and Zampino, Maria Giulia and Fazio, Nicola and Bardelli, Alberto and Siena, Salvatore and Cremolini, Chiara and Sartore-Bianchi, Andrea and Ciardiello, Fortunato},
title = {Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer},
journal = {JAMA Network Open},
year = {2024},
volume = {7},
number = {4},
pages = {e245635},
doi = {10.1001/jamanetworkopen.2024.5635}
}
EUVIMED